The Arizona SciTech Festival is less than two weeks out from sharing a roster of diverse Science, Technology, Mathematics, Engineering and Innovative programs! We will continue to bring our business associates, friends and visitors specific ways to get involved in the most exciting celebration of science and technology wonders our State has ever known!Continue reading→

Beginning in fourth quarter of 2012, AZBio put out the call across Arizona’s bioscience community and asked….”What’ your viewpoint?”

Members of Arizona’s bioscience community from across the state answered via a short survey focused on both policy and action priorities.

Respondents ranked priorities on a scale from 5 to 1 with a 5 being “Most Important”  and a 1 being “Least Important”.

Topping the list for policy priorites is the capital we need to grow, followed closely by policies that attract and grow companies within our industry.

5 Highest Priorities for Public Policy:

1. Access to growth capital  (79% of respondents rating with a 4 or 5 – Average Score 4.1)
2. State and local policies that promote the attraction and growth of companies in the Arizona Bioscience Industry  (75% of respondents rating with a 4 or 5 – Average Score 4.0)
3. Access to a qualified bioscience talent pool (71 % of respondents rating with a 4 or 5- Average Score 3.4)
4. State financial support for the continued growth of Arizona’s research universities  ( 70% of respondents rating with a 4 or 5 – Average Score 3.9)
5. State and local financial support for the continued growth of Arizona’s Medical Schools  (64 % of respondents rating with a 4 or 5- Average Score 3.7)

 Top 5 Priorities for AZBio Actions and Activities

1. Working with Angels, Venture Capital, and Financial Institutions to expand opportunities for Arizona Bioscience Companies to access growth capital.  (80 % of respondents rating with a 4 or 5- Average Score 4.2)
2. Working with educators to promote interest in bioscience education and for their students, interest and preparation for bioscience careers  (74 % of respondents rating with a 4 or 5- Average Score 3.9)
3. Spreading the word about the the value created by Arizona’s Bioscience Industry (72 % of respondents rating with a 4 or 5- Average Score 3.9)
4. Advocating for our industry at the state and local level (71 % of respondents rating with a 4 or 5- Average Score 4.0)
5. Regional Educational Events: Bioscience and Business Speakers  (68 % of respondents rating with a 4 or 5- Average Score 3.7)

To view the AZBio Viewpoint results in 2012, click here.

Survey note:  The AZBio Viewpoint Survey was open to all members of the Arizona bioscience community from November, 2012 until January 2013 and responses were receved from across the state of Arizona.

• 62% of responses were received from Arizona Bioscience Companies and Research Insitutions.
• 80% of responses were received from Arizona Bioindustry Association Member Organizations
• Respondents self represented their company size as follows:
  • 1-10 employees – 48%
  • 11-100 employees – 20%
  • 100+ – 22%

Did you miss participating in the survey?  Additional views are welcome.  To share yours, complete the Viewpoint Survey here .

This morning PhRMA released a report, “Innovation in the Biopharmaceutical Pipeline: A Multi-Dimensional View”. The paper, by researchers at Analysis Group, examines the pipeline from several angles and helps to show the range of innovative research our companies are doing.

The reports find:

• More than 5,000 medicines are in development globally
• 70% of medicines in development are potentially first-in-class
• Personalized medicines and drugs for rare diseases are rapidly growing parts of the drug development pipeline
• Researchers are pursuing many new scientific approaches such as conjugated monoclonal antibodies and therapeutic cancer vaccines

Video streaming by Ustream
PhRMA’s  reports are part of their ongoing efforts to communicate the important contributions PhRMA companies are making to save and improve lives.

Resources

Report: Analysis Group Report

Report: Accompanying PhRMA Report

Release: Robust Biopharmaceutical Pipeline Offers New Hope for Patients

Related Press Coverage USA Today AP News

Related Blog Posts

Examining the Biopharmaceutical Pipeline – Webinar Jan 14, 2013

PhRMA Hosting Webinar Highlighting New Exciting Medicines in the Biopharmaceutical Pipeline January 11, 2013

Company Goals for 2013 Include Introduction of Smaller 50cc Total Artificial Heart and FDA Approval of the Freedom® Portable Driver and HDE for Destination Therapy (Press Release)Continue reading→